Nucala (mepolizumab) effectively induced remission in about half of patients with eosinophilic granulomatosis with polyangiitis (EGPA) that relapsed or did not respond to treatment, according to results from a Phase 3 clinical trial (NCT02020889). The study found that Nucala reduced…
News
Recent Posts
- Low antibody levels common after rituximab for AAV, study shows
- In pursuit of a meaningful life with ANCA vasculitis
- Patient questionnaire captures AAV burdens doctors may miss
- 2 proteins in urine flag kidney failure risk in AAV early on, new study finds
- Approaching MSE as a way to engage in life in meaningful ways